ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1201185
CHEMBL1201185
Compound Name LANREOTIDE
ChEMBL Synonyms SOMATULINE AUTOGEL | LANREOTIDE ACETATE | SOMATULINE DEPOT | LANREOTIDE | SOMATULINE LA | BIM-23014C
Max Phase 4 (Approved)
Trade Names SOMATULINE DEPOT | SOMATULINE LA | SOMATULINE AUTOGEL
Molecular Formula C54H69N11O10S2

Additional synonyms for CHEMBL1201185 found using NCI Chemical Identifier Resolver

Sources

  • British National Formulary
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Molecule Features

CHEMBL1201185 compound icon
Drug Type:Oligopeptide Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Somatostatin receptor 2 agonist Somatostatin receptor 2 DailyMed
Somatostatin receptor 5 agonist Somatostatin receptor 5 DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Carcinoma, Merkel CellD015266EFO:1001471Merkel cell skin cancer2ClinicalTrials
Endocrine Gland NeoplasmsD004701EFO:0003769endocrine neoplasm3ClinicalTrials
Polycystic Kidney, Autosomal DominantD016891EFO:1001496Autosomal dominant polycystic kidney disease3ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm3ClinicalTrials
ClinicalTrials
Esophagitis, PepticD004942EFO:1001095peptic esophagitis2ClinicalTrials
HyperglycemiaD006943HP:0003074Hyperglycemia2ClinicalTrials
Carcinoid TumorD002276EFO:0004243carcinoid tumor2ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma2ClinicalTrials
Graves OphthalmopathyD049970EFO:1001466Graves ophthalmopathy2ClinicalTrials
Rectal NeoplasmsD012004EFO:1000657rectum cancer3ClinicalTrials
DiarrheaD003967HP:0002014diarrhea2ClinicalTrials
Dumping SyndromeD004377EFO:1001307dumping syndrome2ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma3ClinicalTrials
Digestive System DiseasesD004066EFO:0000405digestive system disease2ClinicalTrials
AcromegalyD000172EFO:1001485acromegaly4ClinicalTrials
ClinicalTrials
DailyMed
DailyMed
Malignant Carcinoid SyndromeD008303EFO:1000852carcinoid syndrome3ClinicalTrials

Clinical Data

ClinicalTrials.gov LANREOTIDE
The Cochrane Collaboration LANREOTIDE

HELM Notation

CHEMBL1201185 HELM Notation
PEPTIDE1{[dNal].C.Y.[dW].K.V.C.T.[am]}$PEPTIDE1,PEPTIDE1,7:R3-2:R3$$$

The ChEMBL HELM monomer library is available to download here.

For more details about HELM Notation, please visit the HELM Homepage.

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Compound Cross References

ATC H - SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
H01 - PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H01C - HYPOTHALAMIC HORMONES
H01CB - Somatostatin and analogues
H01CB03 - lanreotide

ChemSpider ChemSpider:PUDHBTGHUJUUFI-SCTWWAJVSA-N
DailyMed lanreotide acetate
Wikipedia Lanreotide

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1201185



BindingDB 82470
ChemicalBook CB6190280
Nikkaji J389.514I
PubChem 6918011
PubChem: Thomson Pharma 14939201 14914752

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/PUDHBTGHUJUUFI-SCTWWAJVSA-N spacer
spacer